Biotinylated Cynomolgus IL-18BP Protein (Primary Amine Labeling) (IL8-CM1BPB)

KACTUS

Biotinylated Cynomolgus IL-18BP Protein (Primary Amine Labeling) (IL8-CM1BPB)

9

Research Use Only

Biotin

>95%

Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.

-80°C

12352202